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Dear Sirs,
Sandhoff disease is a lysosomal storage disease caused by a
deficiency of beta-hexosaminidase. Affected individuals
present with a wide spectrum of clinical manifestations,
ranging from psychomotor impairment and death in the
infantile form to motor neuron disease and autonomic
dysfunction in the adult form [1, 2]. Here, we present a
family with predominantly sensory neuropathy that was
found to have both Sandhoff disease and deficiency of
SH3TC2.
A 46-year-old man had weakness, atrophy, and pares-
thesia with loss of sensation in his hands and feet for
30 years (Fig. 1a). He also had severe diarrhea several
times per week, decreased sweating over his feet, and
episodes of lightheadedness. On examination, he was found
to have marked upper and lower extremity weakness and
muscle atrophy distally, with the legs more severely af-
fected (Fig. 1b). Although hyperreflexia was found in the
upper extremities, reflexes in the lower extremities were
reduced. Electromyography showed evidence of chronic
neurogenic changes, and nerve conduction studies showed
normal motor conduction velocities (patient 40–67 m/s,
sibling 39–58 m/s). However, sensory nerve conduction
studies were non-responsive in the proband and either non-
responsive or reduced in amplitude and velocity (41 m/s)
in the sibling. Autonomic testing (QSWEAT, Heart Rate
Response to Deep Breathing, Valsalva, Tilt Table) and
quantitative sensory testing (Vibratory Detection Threshold
and Cooling Detection Threshold) showed evidence of
autonomic dysfunction consistent with a severe small un-
myelinated fiber and large myelinated fiber sensory neu-
ropathy (Fig. 1d) [3]. Laboratory testing for acquired
causes of neuropathy was negative. An evaluation of the
proband’s 57-year-old sister showed a similar pattern of
sensory, motor, and autonomic involvement, with symptom
onset in her 20s. Both individuals did not show evidence of
macular abnormalities; however, mild splenomegaly was
found in the sister (span 14.2 cm).
After negative genetic testing (Athena Diagnostics Inc.)
of ten candidate neuropathy genes (PMP22, Cx32, MPZ,
PMP22, EGR2, NFL, PRX, GDAP1, LITAF, MFN2), whole
exome sequencing (NISC/NHGRI/NIH) of the proband
identified a common 1250C[T mutation (P417L) in HEXB
and a previously reported [4] 2860C[T mutation (R954X)
in SH3TC2, which was confirmed by Sanger sequencing
(GeneDx). Further testing through multiplex ligation-de-
pendent probe amplification (MLPA, GeneDx) showed that
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the proband is also heterozygous for a 16-kb deletion that
includes exons 1–5 of the HEXB gene. The three variants
were also confirmed in the affected sister, and although two
of the unaffected sisters were found to have the SH3TC2
mutation, neither have both HEXB mutations. MR spec-
troscopy of the superior cerebellar vermis detected elevated
creatine in the proband (Fig. 1c). Serum testing in both
affected siblings showed low total hexosaminidase activity
of 1.4 and 1.0 nmol/min/mL (normal 10.4–23.8) and an
increased fraction of HEXA activity at 91 and 100 %
(normal 56–80 %). A sural nerve biopsy from the proband
showed evidence of a severe mixed axonal and demyeli-
nating neuropathy (Fig. 1e–i) and a reduction in SH3TC2
immunoreactivity (Fig. 1j).
The adult form of beta-hexosaminidase deficiency is
characterized by upper and lower motor neuron dysfunc-
tion, dysautonomia, and ataxia. The amino acid change in
HEXB at position 417 is a common gene mutation in adult
Sandhoff disease patients [5]. The early and severe pre-
sentation of sensory findings in both of these siblings is not
a typical presentation of the disease [6–8]. The nonsense
mutation observed in this family is predicted to reduce
levels of SH3TC2, consistent with the pattern detected on
peripheral nerve staining.
Given the unusual presentation with pronounced sensory
neuropathy in this HEXB family and the evidence of
myelin defects on nerve biopsy, not explained by Sandhoff
disease alone, it is plausible that the deficiency in SH3TC2
may be modifying the HEXB phenotype. SH3TC2 is lo-
calized to the endosome, and disease-causing missense
mutations mistarget the protein away from this location and
result in a demyelinating neuropathy [9]. It is possible that
the accumulation of GM2 ganglioside in HEXB-deficient
endosomes and lysosomes may be preferentially damaging
to tissues that also have a deficiency of SH3TC2.
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bFig. 1 Family pedigree and phenotypical evaluations in the proband.
a Family pedigree. The arrow indicates the proband. Three of the
proband’s sisters were also heterozygous for the SH3TC2 mutation,
but only the two affected individuals had compound heterozygous
mutations in HEXB and the SH3TC2 mutation. A paternal uncle was
diagnosed with amyotrophic lateral sclerosis (ALS). b A photo of the
proband showing atrophy and bluish discoloration of the feet. c MR
spectroscopy (MRS) of the superior cerebellar vermis showing low N-
acetylaspartate (NAA)/creatine ratio, low choline (Cho)/creatine (Cr)
ratio, and normal choline/NAA ratio (the arrow indicates the elevated
creatine peak). MRS of the same location in the proband’s affected
sister showed a low choline/creatine ratio. Normal reference ranges
were established from five controls. d The vibratory detection
threshold (VDT) for the hand, showing increased detection threshold
stimulus magnitude just noticeable difference (JND). Shaded circles
indicate when a stimulus was detected. No stimulus was administered
in trials 2, 4, 12, 14, and 18. The average threshold observed is 19.0
JND (red line), higher than the normative control average of 14.4
JND (blue line). e Hematoxylin and eosin (H?E) staining of the
proband’s sural nerve demonstrating a reduction of large myelinated
nerve fibers; bar 100 lm. f Staining with periodic acid–Schiff (PAS)
(pink) and SH3TC2 (brown) in Schwann cells. Arrow indicates
miniature onion bulb with multiple Schwann cell nuclei. g Luxol fast
staining of a longitudinal section showing evidence of demyelination.
h Gomori trichrome staining showing a reduction in myelin staining
(red) in the patient as compared to control. i PAS staining in patient’s
Schwann cells showing positive staining compared to control.
j Staining with an antibody for SH3TC2 shows a reduction in
staining in the patient compared to control. Bar 50 lm for (f–j)
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